

Request for Proposal

Japanese specialty pharmaceutical company, “EA Pharma Co., Ltd.” is currently seeking drug/target candidates for Pancreatic diseases

EA Pharma Co., Ltd. is a gastrointestinal specialty pharma, established in April 2016 through the integration of the respective gastrointestinal business units of the Eisai Group and the Ajinomoto Group.

EA Pharma Co., Ltd. aims to be a human health care (*hhc*) company that can get close to patients suffering from gastrointestinal diseases through specialized research and development as well as a unique product lineup, and provide a wide range of solutions to patients and their families.

Specializing in gastrointestinal diseases such as pancreatic diseases, we will strive to address unmet medical needs through advanced research and development as well as focusing management resources on marketing activities from the patients’ perspective. The products and the development pipeline of EA Pharma Co., Ltd., as our truck records in gastrointestinal diseases area, are shown on our website. (<https://www.eapharma.co.jp/en/>)

Emphasizing the deep understanding about pathology and actual healthcare situations as well as the ideas inspired by them, EA Pharma Co., Ltd. also introduces external ideas and innovative technologies through public offering of research seeds by academia and research institutes and joint research projects with other companies to create unique value as a specialty pharma.

Pancreatic diseases (Pancreatitis):

1. To seek drug/target candidates that are expected to be highly safe and have preventive and/or therapeutic effect on pancreatitis (acute, recurrent acute, or chronic), in particular by mechanisms that protect acinar cells from necrosis during pancreatitis. Such drug candidates (excluding food constituents) should have high activity, and preferably, its in-vivo efficacy data in the pancreatitis models. It is also preferred that any knock-out and/or transgenic mice for the drug target should be available. The modality includes low-molecular compounds, nucleic acid medicines, antibodies, and peptide medicines.
2. To seek drug/target candidates that are expected to be highly safe and have the decreasing effect on the size of pancreatolithiasis (pancreatic stone) size.
3. To seek animal models of pancreatolithiasis available for the evaluation of the anti-pancreatolithiasis drug candidates above.
4. To seek technologies that enable specific delivery of nucleic acids, peptides, etc. to the pancreas, preferentially pancreatic acinar cells or ductal cells.

Items to be submitted:

- Overview of the technology (features, competitive advantage, etc.)
- Overview of the organization and prior results
- Desired collaboration type (if any)
- Other

Evaluation items (but not necessarily cover all the items for the initial evaluation) :

The client will evaluate all responses with the following criteria.

- Proposed technology/project/organization overview, performance
- Feasibility of achieving the target specifications
- Economic potential of concept
- Possibilities of ownership (exclusive right, priority right, etc.)
- Related experiences

Notes:

- By submitting a proposal, you declare that the proposal does not and will not contain any kind of confidential information.
- Your Proposal should be an executive summary (free format, within 5 pages, including figures and tables) in English.

Application method, period, inquiry:

- Apply and make inquiries online <https://www.foundry.japantechnologygroup.com/sp>
- Closing date for application: **November 30, 2018**
- JTG will provide a feedback for all applicants by the end of December, 2018 by e-mail
- Please contact via the e-mail if you have a question
at myamamoto@japantechnologygroup.com and heading “Attention: Y18L010”.